CareDx, Inc (CDNA)
After hours:
| Previous Close | 23.68 |
| Open | 24.08 |
| Bid | 23.03 x 800 |
| Ask | 26.45 x 1300 |
| Day's Range | 22.89 - 24.08 |
| 52 Week Range | 19.34 - 96.88 |
| Volume | |
| Avg. Volume | 932,587 |
| Market Cap | 1.25B |
| Beta (5Y Monthly) | 0.81 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.95 |
| Earnings Date | Jul 27, 2022 - Aug 01, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 59.00 |
- Business Wire
CareDx The Transplant Company Releases Inaugural Environmental, Social and Governance Report
SOUTH SAN FRANCISCO, Calif., June 21, 2022--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the release of its first environmental, social and governance (ESG) report.
- Business Wire
CareDx To Participate in Upcoming Jefferies Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 02, 2022--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in the Jefferies Healthcare Conference on June 9th, 2022.
- Business Wire
CareDx Leads Transplant Innovation with AiKidney, an AI Clinical Decision Support Tool for Predicting Allograft Rejection Risk
SOUTH SAN FRANCISCO, Calif., June 02, 2022--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it plans to expand its growing multimodality portfolio with AiKidney™, a new allograft risk assessment clinical decision support tool, in development, that includes AlloSure® and other transplant metrics.
